Table 3.
Pathway enrichment analysis of common DEGs among COVID-19 and RA.
| Category | Pathways | P-values | Genes |
|---|---|---|---|
| KEGG 2021 Human | Hematopoietic cell lineage | 5.71E-08 | CD1C/HLA-DPB1/HLA-DRA/HLA-DPA1/FCGR1A/HLA-DMA/CD3E/IL7R/IL1R2 |
| Staphylococcus aureus infection | 6.50E-07 | HLA-DPB1/HLA-DRA/HLA-DPA1/FCGR1A/HLA-DMA/C2/DEFA4/CAMP | |
| Leishmaniasis | 1.90E-06 | EEF1A1/HLA-DPB1/HLA-DRA/HLA-DPA1/FCGR1A/HLA-DMA/TLR2 | |
| Th1 and Th2 cell differentiation | 6.33E-06 | HLA-DPB1/HLA-DRA/HLA-DPA1/HLA-DMA/CD3E/LCK/STAT4 | |
| Tuberculosis | 9.01E-06 | HLA-DPB1/HLA-DRA/HLA-DPA1/FCGR1A/HLA-DMA/CD74/TLR2/CLEC4E/CAMP | |
| Inflammatory bowel disease | 9.95E-06 | HLA-DPB1/HLA-DRA/HLA-DPA1/HLA-DMA/STAT4/TLR2 | |
| Rheumatoid arthritis | 7.75E-05 | HLA-DPB1/HLA-DRA/HLA-DPA1/HLA-DMA/TLR2/CCL5 | |
| Asthma | 8.88E-05 | HLA-DPB1/HLA-DRA/HLA-DPA1/HLA-DMA | |
| Phagosome | 1.62E-04 | HLA-DPB1/HLA-DRA/HLA-DPA1/FCGR1A/HLA-DMA/TLR2/MARCO | |
| Th17 cell differentiation | 1.78E-04 | HLA-DPB1/HLA-DRA/HLA-DPA1/HLA-DMA/CD3E/LCK | |
| Allograft rejection | 2.00E-04 | HLA-DPB1/HLA-DRA/HLA-DPA1/HLA-DMA | |
| Human T-cell leukemia virus 1 infection | 2.94E-04 | CCNE2/HLA-DPB1/HLA-DRA/HLA-DPA1/HLA-DMA/CD3E/LCK/IL1R2 | |
| Graft-versus-host disease | 2.96E-04 | HLA-DPB1/HLA-DRA/HLA-DPA1/HLA-DMA | |
| Type I diabetes mellitus | 3.25E-04 | HLA-DPB1/HLA-DRA/HLA-DPA1/HLA-DMA | |
| Antigen processing and presentation | 3.28E-04 | HLA-DPB1/HLA-DRA/HLA-DPA1/HLA-DMA/CD74 | |
| Coronavirus disease - COVID-19 | 3.95E-04 | RPS3/RPL13A/RPL13/RPSA/RPL3/RPL18/TLR2/C2 | |
| Intestinal immune network for IgA production | 5.39E-04 | HLA-DPB1/HLA-DRA/HLA-DPA1/HLA-DMA | |
| Systemic lupus erythematosus | 6.17E-04 | HLA-DPB1/HLA-DRA/HLA-DPA1/FCGR1A/HLA-DMA/C2 | |
| Autoimmune thyroid disease | 7.27E-04 | HLA-DPB1/HLA-DRA/HLA-DPA1/HLA-DMA | |
| Epstein-Barr virus infection | 9.08E-04 | CCNE2/HLA-DPB1/HLA-DRA/HLA-DPA1/HLA-DMA/CD3E/TLR2 | |
| Viral myocarditis | 1.16E-03 | HLA-DPB1/HLA-DRA/HLA-DPA1/HLA-DMA | |
| Ribosome | 1.35E-03 | RPS3/RPL13A/RPL13/RPSA/RPL3/RPL18 | |
| Toxoplasmosis | 1.71E-03 | HLA-DPB1/HLA-DRA/HLA-DPA1/HLA-DMA/TLR2 | |
| Primary immunodeficiency | 3.10E-03 | CD3E/LCK/IL7R | |
| Prostate cancer | 6.68E-03 | CCNE2/MMP9/FGFR2/IL1R2 | |
| Malaria | 6.75E-03 | KLRB1/KLRK1/TLR2 | |
| Arginine and proline metabolism | 7.13E-03 | MAOB/ARG1/MAOA | |
| Viral protein interaction with cytokine and cytokine receptor | 7.43E-03 | CCR7/CCL5/CXCL9/PPBP | |
| Phenylalanine metabolism | 7.49E-03 | MAOB/MAOA | |
| Cytokine-cytokine receptor interaction | 7.58E-03 | IL32/IL7R/CCR7/CCL5/CXCL9/IL1R2/PPBP |